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Abstract  29 
Trip Doctor®, a Smartphone-based app monitoring system, was developed to detect 30 
infections among travelers in real-time. For testing, 106 participants were recruited 31 
(62.2% male, mean age 36 years (SD=11)). Majority of trips were for tourism and main 32 
destinations were in South East Asia. Mean travel duration was 14 days (SD=10). 33 
Diarrhea was the most frequently reported symptom (15.5%). The system demonstrated 34 
adequate usability and is ready to be used on a larger scale. 35 
  36 
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Introduction 37 
International travel have been steadily growing for six consecutive decades, with an 38 
estimated increase of 3.3% per year in tourism and, only in 2015, 14% of travels were 39 
related to business. 1 A greater increase is observed and forecasted in travel to tropical 40 
and subtropical destinations in Asia, America and Africa. A median of 51% 41 
(Interquartile range: 6-87%)2  travellers are estimated to present travel-related 42 
symptoms during or after the travel, of them up to 55% seek medical care during the 43 
trip2 , additionally in some reports, at least 21% of the travelers stopped their planned 44 
activities due to illness.3 Most studies evaluating travel-related infections2 are based on 45 
questionnaires conducted in post-travel clinics in symptomatic travelers once returned, 46 
conferring strong recall bias, providing inaccurate temporal symptom sequence and not 47 
taking into account the number of asymptomatic travelers to calculate incidence rates. 48 
The most common symptoms of travel-related infections shown in previously published 49 
studies are: fever (8-17%), travelers’ diarrhea (33-69%) and cutaneous lesions (7-50 
17%).3,4,5 51 
A way to overcome the limitations cited above is the use of telemedicine. There are 52 
many mobile applications for travel medicine6,7 but few of them evaluating health travel 53 
risks real-time.8 54 
Our aim was to develop and test a new telemedicine and digital participatory system in 55 
order to detect travel related-symptoms and provide with remote care to the travelers 56 
attending our travel clinic; alongside testing the surveillance capacity of the system. 57 
Methods 58 
Our group developed and tested a Smartphone-based app remote digital participatory 59 
and monitoring system9 to detect symptoms of the main infectious diseases among 60 
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international travelers in real-time, called Trip Doctor®. The app was uploaded in 61 
PlayStore® and Apple Store® to be used with a code that we provided to the travelers 62 
after agreed to participate into the study. Trip Doctor® app monitored the status of the 63 
travelers on a daily basis at a predetermined time, providing specific medical advice and 64 
offering remote contact with the study physicians to those reporting symptoms. All 65 
travel and clinical data, including malaria prophylaxis indication and intake, travel 66 
dates, and purpose of travel, health status and symptoms, and approximate daily 67 
geolocation, for each health check during travel, were recorded automatically in a 68 
specific web back-end remote monitoring system. Real-time data of participants could 69 
be visualized by medical specialists through the web monitoring system and could be 70 
transformed into a dataset automatically for the purpose of analyzing the data (Figure 71 
1). Trip Doctor® app was developed following privacy by design strategies so only 72 
medical specialists monitoring the backend can access to patient information.  73 
Additionally the app acted as a reminder for malaria prophylaxis in case it was indicated 74 
by the attending physician. Daily predetermined symptoms captured were “diarrhea”, 75 
“abdominal pain”, “fever”, “joint pain”, “headache”, “cutaneous lesions” and “other”. 76 
Symptoms were chosen by the medical team of the study in order to detect the most 77 
frequent symptoms associated to the main tropical infections including those posing a 78 
risk of the traveler abroad. Moreover, possible associated symptoms of malaria 79 
chemoprophylaxis were also recorded in the database: oral ulcers, insomnia. A real-time 80 
alarm system was implemented in the database to automatically identify travelers with 81 
symptoms compatible with arboviral disease (defined as fever + joint pain + travelling 82 
to an area endemic for arbovirus) to test the system’s potential to contribute to the 83 
identifications of suspects to control the introduction of arboviral diseases in Spain. All 84 
travelers were followed-up during 21 days after the travel. 85 
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This study was approved by the Ethics Committee of Hospital Clinic Barcelona 86 
(reference HCB/2015/0995) and the clinical investigation has been conducted according 87 
to the principles expressed in the Declaration of Helsinki. A written informed consent 88 
was signed by the participants before using the Trip Doctor®. 89 
We invited to participate in this pilot study those travelers attending our pre-travel clinic 90 
older than 18 years and travelling for one month or less. Travelers taking malaria 91 
chemoprophylaxis with other drugs than atovaquone-proguanil were excluded due to 92 
safety because the App was not configured to remind other prophylaxis schemes than 93 
atovaquone-proguanil.  94 
Results 95 
During the study period 106 travelers agreed to participate in the study. Mean age was 96 
36 years (SD=11) and 62.2% were male. The most visited regions were Sub-Saharan 97 
Africa 34.6%, followed by South East Asia 32%, Americas 16.4%, Western Pacific 98 
16% and Eastern Mediterranean 1.9%.The top 5 destination countries were: Thailand 99 
(12%), followed by India (8%) and Indonesia (8%), Mozambique (6%) and China (5%). 100 
Mean duration of travel was 14 days (SD=10). The main purpose of travel was tourism 101 
in 58%, followed by work 30%, volunteering or humanitarian work 9% and Visiting 102 
Friends and Relatives (VFR) 3%. Thirty three percent of participants were prescribed 103 
with malaria chemoprophylaxis for a mean duration of 15 days (SD=6).  104 
Incidence rates of recorded symptoms are shown in Table 1. No associations between 105 
symptoms were observed with sex, purpose of travel, age, duration of the trip or 106 
prophylaxis status. Moreover, no cases fulfilling the definition of arbovirus suspicion 107 
were found during the period of the study. 108 
During the period of the study 2 telemedicine calls were received, both for mild 109 
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abdominal pain associated with constipation and they could be resolved by telemedicine 110 
itself. No further medical visits were needed. During the follow-up period, a phone 111 
interview was made to all participants, at least 3 patients sought medical care abroad, 112 
two of them because of diarrhea and fever, but no more information could be collected. 113 
In terms of usability, number mean of days with a complete daily health check for all 114 
users was 9.9 (SD=6.9) and number mean of days not using the App, meaning not 115 
completing the health daily check,  was 5.7 (SD=8.8). The participants used the app, 116 
completing the health daily check, more than 50% of the days of the travel. 117 
Discussion 118 
We evaluated the new Smartphone app Trip Doctor® in a pilot study to show that our 119 
remote monitoring system is able to capture real-time incidence of travel-related 120 
infections, together with a number of epidemiological and geographical data that can be 121 
evaluated as risk factors for disease in further studies. The platform allows overcoming 122 
common limitations of conventional studies: providing a reliable time sequence of 123 
medical events, avoiding recall bias, and providing a denominator of healthy travelers to 124 
calculate incidence rates, as well as offering care to travelers if necessary. 125 
The main limitation of this pilot study is the small number of participants and the short 126 
duration of travel, this is reflected in the absence of association between symptoms and 127 
duration of travel, a main factor for illness in other studies.4,5 Other limitations are those 128 
related to generalizability, our cohort is a selected population who attend to a travel 129 
clinic and that fact could influence their behavioral risk. Also, VFR and vulnerable 130 
population (pregnant women, children and people aged more than 65 years) are not well 131 
represented.  132 
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In spite of these limitations, it was shown that 13% of them presented at least one 133 
symptom of travel-related infection, with diarrhea and abdominal pain the most 134 
common in 15% of the cases, less than in other studies.10,5.  135 
Conclusion 136 
This is a pilot test of a broader initiative to implement remote monitoring of health in 137 
travelers to high risk areas. If scaled-up, the outputs of this initiative will facilitate big 138 
data analysis, providing a better understanding of health-related risks for travelers and 139 
having a positive impact in pre-travel advice and disease prevention. This traveler’s 140 
platform could be then used as a surveillance mechanism for the epidemiology of 141 
infectious imported diseases, enhancing mechanisms to control the introduction of 142 
infectious diseases (in particular arboviral diseases) in countries at-risk harboring Aedes 143 
mosquitoes. Moreover, tracing traveler’s symptoms could be an excellent data source to 144 
detect outbreaks of infectious diseases in remote destinations in a real time basis. 145 
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Table1. Incidence of travel-associated symptoms during travel in the cohort (N=106) 188 
 189 
 190 
Symptom (for a 12 day 
mean travel) Accumulated incidence or incidence 
proportion 
Incidence 
Rate* 
Diarrhea 15.5% 1.4% 
Abdominal pain 13.1% 1.2% 
Articular pain 8.3% 0.8% 
Headache 9.5% 0.9% 
Cutaneous lesions 9.5% 0.9% 
Other symptoms 10.7% 1% 
Fever 3.6% 0.3% 
Oral ulcers  3.6% 0.3% 
Insomnia 3.6% 0 
*cases person-day   
 191 
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